Evaluation of reimbursement policy about anti-tnf agents in Turkey
[ X ]
Tarih
2019
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Soc Stiinte Farmaceutice Romania
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Anti-TNF (anti-tumour necrosis factor) agents are currently used in many rheumatic diseases. This research aims mainly to evaluate the reimbursement policy about anti-TNF drugs in Turkey. The analysis has been carried out according to the antiTNF reimbursement rules with the consumption data for the years 2012 - 2017. The cost tables have been prepared with the reimbursement prices and the medication prospectus doses approved by Turkish Ministry of Health. The results of the research indicate that anti-TNF agents have different treatment costs and adalimumab offers the lowest 12-month treatment costs for the diseases mentioned in the study. For a fair, obtainable and sustainable medication policy, Social Security Administration (SSA) has to reimburse the other molecules from the 12-month treatment cost of adalimumab. The current policies are far from being pharmacoeconomic and if this continues the resources will not be used in an efficient way for public health in Turkey.
Açıklama
Anahtar Kelimeler
Anti-TNF Agents, Cost Analysis, Turkish Health System, Pharmacoeconomics
Kaynak
Farmacia
WoS Q Değeri
N/A
Scopus Q Değeri
Cilt
67
Sayı
4
Künye
Bilginer, E. (2019). Evaluation of reimbursement policy about anti-tnf agents in Turkey. Farmacia, 67(4), 743-748.
